Background. Surgeons may receive a different diagnosis when a breast biopsy is interpreted by a second pathologist. The extent to which diagnostic agreement by the same pathologist varies at two time points is unknown. Methods. Pathologists from eight U.S. states independently interpreted 60 breast specimens, one glass slide per case, on two occasions separated by C9 months. Reproducibility was assessed by comparing interpretations between the two time points; associations between reproducibility (intraobserver agreement rates); and characteristics of pathologists and cases were determined and also compared with interobserver agreement of baseline interpretations. Results. Sixty-five percent of invited, responding pathologists were eligible and consented; 49 interpreted glass slides in both study phases, resulting in 2940 interpretations. Intraobserver agreement rates between the two phases were 92% [95% confidence interval (CI) 88-95] for invasive breast cancer, 84% (95% CI 81-87) for ductal carcinoma-in-situ, 53% (95% CI 47-59) for atypia, and 84% (95% CI 81-86) for benign without atypia. When comparing all study participants' case interpretations at baseline, interobserver agreement rates were 89% (95% CI 84-92) for invasive cancer, 79% (95% CI 76-81) for ductal carcinoma-in-situ, 43% (95% CI 41-45) for atypia, and 77% (95% CI 74-79) for benign without atypia. Conclusions. Interpretive agreement between two time points by the same individual pathologist was low for atypia and was similar to observed rates of agreement for atypia between different pathologists. Physicians and patients should be aware of the diagnostic challenges associated with a breast biopsy diagnosis of atypia when considering treatment and surveillance decisions.
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Mammography screening has increased the identification of noninvasive lesions such as atypia (including atypical ductal hyperplasia) and ductal carcinoma-in-situ (DCIS). [1] [2] [3] These lesions are associated with increased risk for breast cancer and thus generate anxiety, additional testing, surveillance, and treatment. Practice guidelines for women with atypia and DCIS include enhanced annual screening with magnetic resonance imaging and pharmacologic risk reduction with selective estrogen receptor modulators or aromatase inhibitors. 4 Some women go so far as to request prophylactic bilateral mastectomies. 5, 6 Surgeons need to rely on the pathologic interpretation, the reference standard for breast tissue diagnosis; however, disagreement among pathologists on noninvasive lesions, such as atypia and some forms of DCIS, has been reported. [7] [8] [9] [10] [11] Concerns about challenges interpreting these biopsy specimens lead many to obtain second opinions before initiating treatment. [12] [13] [14] While established diagnostic criteria exist to guide pathologists in breast tissue interpretation, the extent of disagreement among pathologists on diagnoses of atypia led us to question the reproducibility of the diagnoses. 15, 16 That is, would pathologists diagnose atypia on a case they had previously interpreted as such? Is the underlying cause for variability the pathologist or the case? Few studies assess intraobserver agreement for breast diagnoses such as atypia. 17 Therefore, we studied agreement rates for individual pathologists who interpreted the same cases at different times, hypothesizing greater consistency with their own diagnosis than with interpretations by other breast pathologists. We examined results from 49 pathologists participating in the Breast Pathology (B-Path) study who interpreted one slide per test case at two points in time separated by at least 9 months (intraobserver agreement). We then compared the levels of intraobserver agreement with interobserver agreement.
METHODS

Study Participants
The B-Path study recruited pathologists from eight U.S. states: Alaska, Maine, Minnesota, New Hampshire, New Mexico, Oregon, Vermont, and Washington. Pathologists who interpreted breast specimens within the prior year and planned to continue in the following year were eligible unless they were in training. Other aspects of identification and recruitment have been previously reported. 18 Demographic data, practice characteristics, and interpretive experience of the pathologists were queried using a Webbased survey. 13, 18 Test Set Cases and Consensus Reference Diagnoses Using a random stratified sampling method, core needle or excisional breast biopsy samples from the New Hampshire and Vermont breast pathology registries from the National Cancer Institute-sponsored Breast Cancer Surveillance Consortium were selected for the test set of 240 cases as previously described. 19 Cases were stratified to reflect an even distribution of ages (49% aged 40-49 years; 51% aged C50 years) and breast density (51% heterogeneously or extremely dense on mammography). Cases of atypia and DCIS were oversampled; among the 240 test cases, 30%
were benign without atypia, 30% were atypia, 30% were DCIS, and 10% were invasive carcinoma. Three experienced and internationally recognized breast pathologists interpreted all test cases and assigned a difficulty level for each case. 11 The 240 cases were randomly assigned to one of four different test sets (60 cases each) that were stratified by the woman's age, breast density, the expert panel consensus reference diagnosis, and the experts' difficulty rating. 11 
Study Procedure
In phase 1, participants independently interpreted 60 cases based on one glass slide per case. In phase 2, the same participants reinterpreted the same 60 cases at least 9 months after phase 1. The glass slides in phase 2 were randomly reordered and the participants were not told they were reviewing the same cases. After phase 2, pathologists were queried regarding whether they thought any of the cases in the second set (phase 2) were the same as those in the first set (phase 1). Because pathologists were randomly assigned to one of four test sets of 60 cases each, all 240 test cases contributed interpretive data to the study. Diagnostic assessments were recorded using an online assessment tool developed for the study, the Breast Pathology Assessment Tool and Hierarchy for Diagnosis (BPATH-Dx). 11, 20 Fourteen distinct diagnostic assessments were categorized into four main BPATH-Dx categories: (1) benign without atypia (including nonproliferative and proliferative without atypia); (2) atypia (atypical ductal hyperplasia and intraductal papilloma with atypia); (3) DCIS; and (4) invasive breast carcinoma. For each case, when multiple diagnostic assessments were noted on an individual case, the most severe diagnosis was assigned as their primary diagnosis. Participants could also indicate whether they considered the case to be borderline between two diagnoses; when they noted that a case was borderline, they were prompted to provide a second diagnosis on the case.
Human Research Protections
The Institutional Review Boards of Dartmouth College, the Fred Hutchinson Cancer Research Center, Providence Health & Services of Oregon, the University of Vermont, and the University of Washington approved all study procedures. All participating pathologists signed an informed consent.
Statistical Analyses
We compared phase 1 versus phase 2 categorical diagnoses to determine the proportion of phase 2 interpretations that agreed with phase 1. We then repeated the comparison, accounting for cases considered ''borderline'' between two diagnoses on the second interpretation. If a borderline diagnosis in phase 2 included the diagnosis recorded for phase 1, the participant was given credit for interpretive agreement. Next, we compared individual pathologist interpretations in phase 1 to interpretations of the same slide by any other pathologist in phase 2, resulting in 33,120 paired comparisons (552 paired pathologists 9 60 cases = 33,120 assessments).
Lastly, we assessed participant, case, and phase 1 interpretative assessment characteristics associated with diagnostic intraobserver agreement in both study phases. All reported case characteristics were assessed at the time of the phase 1 interpretation. Separate logistic regression analyses tested associations between interpretive agreement (yes vs. no) of pathologist, case, and phase 1 interpretative assessment characteristics. We used generalized estimating equations methodology for model fitting, hypothesis testing, and confidence interval construction. This logistic regression methodology was used without covariates (Tables 1, 2; Fig. 1 ) to derive confidence intervals for interpretative agreement in phase 2 restricted to cases with specific diagnostic interpretations in phase 1. Finally, we examined associations between interpretive agreement and pathologist and case characteristics restricting to cases interpreted as atypia in phase 1. p values were two-sided. All statistical analyses were performed by SAS 9.4 for Windows (SAS Institute, Cary, NC).
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RESULTS
Intraobserver and Interobserver Diagnostic Agreement Rates
Forty-nine pathologists provided a total of 2940 interpretations for each phase. Agreement rates were 92% [95% confidence interval (CI) 88-95] for invasive cancer; 84% (95% CI 81-87) for DCIS; 53% (95% CI 47-59) for atypia; and 84% (95% CI 81-86) for benign without atypia (Table 1) . When pathologist interpretations were compared to all other interpretations of the same slide by peer study participants (33,120 paired comparisons), agreement rates were 89% (95% CI 84-92) for invasive cancer; 79% (95% CI 76-81) for DCIS; 43% (95% CI 41-45) for atypia; and 77% (95% CI 74-79) for benign without atypia (Table 2) .
When we broadened the definition of agreement to include when either the primary or secondary diagnosis from phase 2 agreed with the phase 1 diagnosis, agreement rates were: 97% (95% CI 94-98) for invasive carcinoma; 91% (95% CI 88-93) for DCIS; 58% (95% CI 53-64) for atypia; and 84% (95% CI 81-86) for benign without atypia Fig. 1 ).
Association of Participant and Case Characteristics with Reproducibility
No statistically significant associations were noted between pathologists' reproducibility of their diagnoses and any of the measured pathologist characteristics. When analysis was limited to cases interpreted as atypia in phase 1, pathologists who reported that their colleagues considered them experts in breast pathology had higher reproducibility (intraobserver agreement rates) than nonexperts (65% compared to 50% agreement, p = 0.010) ( Table 3) . Lower breast density was associated with slightly higher reproducibility (intraobserver agreement rates) when all cases were considered (p = 0.007), but not for cases interpreted as atypia in phase 1 (Table 4 ). Agreement was also higher when pathologists assigned fewer diagnoses per case in phase 1 (p \ 0.001), but this association was not demonstrated for atypia cases. For atypia, agreement was higher with tissue obtained by core needle biopsy compared to excisional biopsy (p = 0.037) ( Table 4) .
Overall, pathologists had greater reproducibility (intraobserver agreement) if they reported higher levels of confidence or less difficulty with the case in phase 1, if the case was not borderline between two diagnoses, or if they did not want a second opinion. This was also observed when restricted to interpretations of atypia in phase 1 ( Table 5) .
DISCUSSION
When pathologists interpreted the same slide from a set of breast biopsy test cases at two points in time, their interpretative agreement varied according to diagnostic category. While reproducibility (intraobserver agreement) was high for invasive breast carcinoma cases, it was lower for DCIS, and for atypia it was just 53%. Pathologists' intraobserver agreement was higher than their interobserver agreement with other study pathologists, and for atypia the interobserver agreement was 43%. While pathologists are more likely to agree with their own previous diagnoses than with diagnoses by other pathologists, we note concerning findings with regard to the middle diagnostic categories. No pathologist characteristics, such as training or experience, were associated with improved reproducibility. As one would expect, cases that pathologists rated as difficult or borderline between two diagnoses, or where a second opinion was desired, had lower reproducibility. This suggests that pathologists are aware of cases with potentially low diagnostic agreement. Clinical decisions based on pathologic diagnoses of atypia should be interpreted in light of these results. Breast atypia is not reproducibly identified, even by the same pathologist, calling into question whether clinicians and women should make clinical decisions based on the pathology report without additional supporting opinions, ancillary diagnostic markers, and taking the full clinical presentation into consideration. It is also possible that similar ''indolent lesions of epithelial origin'' in other organ systems may lack diagnostic reproducibility, and further study is needed. 21 Pathologists in this study had consistently low agreement for atypia diagnoses, whether compared to their own prior diagnosis, their peer study participants' diagnoses, or to the consensus diagnosis of an expert panel of three breast pathologists. A prior analysis compared breast diagnoses of a larger cohort of pathologists interpreting these test cases to diagnoses of an expert reference panel consensus. 11 Compared to experts, diagnostic agreement was 96% for invasive carcinoma, 84% for DCIS, 48% for atypia, and 87% for benign without atypia. 11 Pathologists with higher weekly case volumes or who work in larger or academic practice settings had higher agreement rates with an expert panel. 11 However, these factors were not associated with intraobserver diagnostic consistency in the current study, which could be due to the smaller sample size. Thus, the consistently low reproducibility for atypia does not appear to be related to pathologists' training and diagnostic acumen, but instead is likely due to inherent characteristics of the tissue specimen and an inability to classify these lesions adequately. This may be due to inherent image complexity of microscopic epithelial characteristics of the individual case, or the diagnostic criteria may be more susceptible to subjective interpretation. In addition, the atypia category may encompass greater intrinsic biologic variability, relative to other diagnostic categories, making differences in agreement less likely to be attributable to the interpreter. 20 The low reproducibility for atypia is particularly problematic because a diagnosis of atypia implies an increased future risk for invasive cancer, can lead to more intensive surveillance and treatment, and can lead to an excisional biopsy if the diagnosis is made on a core biopsy. Wide diagnostic variation for atypia between pathologists has been previously documented. [7] [8] [9] [10] One study of atypia diagnoses by nine pathologists found that intraobserver kappa values were higher (0.56 to 0.80) than the interobserver kappa (0.34). The addition of immunohistochemical stains improves the agreement rate and decreases atypia diagnoses in favor of usual hyperplasia, which would decrease surgical intervention for these lesions. 17, 22 Our intraductal papilloma with atypia, (10) atypical lobular hyperplasia, (11) atypical ductal hyperplasia, (12) lobular carcinoma-in-situ, (13) ductal carcinoma-in-situ, (14) invasive breast carcinoma study presents intraobserver data on a much larger sample of pathologists who work in multiple geographic areas of the United States, but our methods did not incorporate the option of additional diagnostic test results such as immunohistochemical stains, which might improve observed agreement for atypia. The statistically significant relationship between intraobserver agreement and fewer diagnoses for a case probably reflects epithelial complexity or overlapping diagnostic features (diagnostic distraction). Similarly, the association of higher breast density with lower reproducibility suggests that inherent characteristics of the breast tissue increase the diagnostic challenge. Our previous studies found that accuracy was slightly higher when pathologists used glass slides, as the current study did, compared to digital whole slide imaging (WSI), an emerging technology for pathology interpretation. 18 Although currently understudied, intraobserver variability also has the potential to be greater using WSI.
Strengths of the study include the enrollment of a large number of pathologists from multiple geographic regions in the United States who interpreted 60 cases at least 9 months apart. The increased proportion of DCIS and atypia cases allows power for statistical comparisons. When compared to the entire spectrum of breast pathology seen in their own practices, 74% (n = 70) of B-Path participants who completed the CME activity (n = 94) reported that they either often or always see cases like these, 22% (n = 21) reported sometimes seeing cases like these, and 3% (n = 3) did not respond to the question. Because the proportion of atypia and DCIS cases in this study was higher than in typical clinical practice and because second consultative opinions were not allowed, agreement rates are lower than would be expected for clinical settings, where the prevalence of these challenging diagnoses is lower and additional evaluation is common. Further, statistically significant associations between pathologist characteristics, case characteristics, and interpretive agreement could be a consequence of multiple statistical comparisons. Lastly, because of testing conditions, pathologists only interpreted one slide per case, without the benefit of additional clinical information (except for age and biopsy type) or supplemental immunohistochemical test results-conditions which differ from clinical practice.
In conclusion, an individual pathologist's agreement with his or her own interpretations of breast biopsy samples at a second point in time varies; the lowest observed agreement rates were for atypia and the highest were for 
